Local drugmakers to challenge Baraclude in generics fight

Published: 2012-09-19 07:00:00

Updated: 2012-09-19 07:00:00

Korean pharmaceutical firms are gearing up to enter the 100 billion won anti-hepatitis B drug market as the patent of the market leader, Bristol-Myers Squibb (BMS)’s Baraclude (entecavir), is to expire in 2015.

The Korea Food and Drug Administration said last Friday that it has approved the ge...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK